<p>Apellis Pharmaceuticals（纳斯达克代码：APLS - 获取免费报告）于周四公布了其财报。该公司报告本季度每股收益为 0.15 美元，超出市场共识预期的（0.38 美元）0.53 美元，FiscalAI 报道。Apellis Pharmaceuticals 的净利润率为 2.23%，股本回报率为 8.20%。该季度的营业收入为 2.683 亿美元，而分析师的预期为 2.0358 亿美元。</p>
<h2>Apellis Pharmaceuticals 股价下跌 0.3%</h2>
<ul>
<li>Beam Therapeutics 因基因治疗许可支付而大幅上涨</li>
</ul>
<p>周四午盘交易中，纳斯达克代码：APLS 的股价下跌 0.11 美元，报 41.01 美元。该股票的交易量为 8,392,532 股，而其平均交易量为 3,822,692 股。Apellis Pharmaceuticals 的 12 个月低点为 16.10 美元，12 个月高点为 41.14 美元。该公司的速动比率为 2.70，流动比率为 3.14，债务股本比率为 0.98。该公司的 50 日简单移动平均线为 30.34 美元，200 日简单移动平均线为 25.59 美元。公司的市值为 52.5 亿美元，市盈率为 315.49，贝塔值为-0.24。</p>
<h2>对 Apellis Pharmaceuticals 的对冲基金看法</h2>
<p>几家对冲基金和其他机构投资者最近对该公司的持仓进行了调整。Invesco Ltd.在第四季度将其在 Apellis Pharmaceuticals 的股份增加了 23.5%。Invesco Ltd.目前拥有 225,976 股该公司的股票，价值 5,677,000 美元，此前在上个季度又购买了 42,960 股。Mackenzie Financial Corp 在第四季度将其在 Apellis Pharmaceuticals 的股份增加了 25.4%。Mackenzie Financial Corp 目前拥有 96,211 股该公司的股票，价值 2,424,000 美元，此前在上个季度又购买了 19,500 股。NewEdge Advisors LLC 在第四季度购买了 Apellis Pharmaceuticals 的新头寸，价值 366,000 美元。Virtus Investment Advisers LLC 在第四季度将其在 Apellis Pharmaceuticals 的股份增加了 17.4%。Virtus Investment Advisers LLC 目前拥有 27,086 股该公司的股票，价值 680,000 美元，此前在上个季度又购买了 4,013 股。最后，Twinbeech Capital LP 在第四季度将其在 Apellis Pharmaceuticals 的持仓增加了 47.3%。Twinbeech Capital LP 目前拥有 13,152 股该公司的股票，价值 330,000 美元，此前在此期间又购买了 4,225 股。96.29% 的股票由机构投资者持有。</p>
<h2>分析师设定新目标价</h2>
<ul>
<li>小型股是否预示市场下跌？</li>
</ul>
<p>几位研究分析师最近对该股票进行了评论。美国银行将 Apellis Pharmaceuticals 的股票评级从 “中性” 上调至 “买入”，并在 1 月 21 日的报告中设定了 28.00 美元的目标价。摩根大通在 4 月 1 日的报告中重申了 “中性” 评级，并将 Apellis Pharmaceuticals 的目标价设定为 41.00 美元（上调自 37.00 美元）。巴克莱在 4 月 1 日的报告中将 Apellis Pharmaceuticals 的目标价从 24.00 美元提高至 41.00 美元，并给予该股票 “等权重” 评级。雷蒙德·詹姆斯金融在 4 月 1 日的报告中将 Apellis Pharmaceuticals 的股票评级从 “适度买入” 下调至 “持有”。最后，富国银行在 4 月 17 日的报告中将 Apellis Pharmaceuticals 的股票评级从 “超配” 下调至 “等权重”，并将该股票的目标价从 26.00 美元提高至 41.00 美元。三位股票研究分析师对该股票给予了买入评级，十八位给予了持有评级，两位给予了卖出评级。根据 MarketBeat.com 的数据，Apellis Pharmaceuticals 目前的平均评级为 “持有”，共识目标价为 34.89 美元。</p>
<p><strong>查看我们最新的 APLS 研究报告</strong></p>
<h2>Apellis Pharmaceuticals 公司简介</h2>
<p>（获取免费报告）</p>
<p>Apellis Pharmaceuticals, Inc.，以纳斯达克代码：APLS 交易，是一家临床阶段的生物制药公司，专注于开发针对补体级联反应的新疗法，以治疗罕见且严重的疾病。该公司的研发工作集中在调节补体蛋白，以解决一系列眼科、血液和肾脏疾病。Apellis 利用其专有的 compstatin 技术平台设计针对性抑制剂，旨在改善患者的治疗效果和生活质量。</p>
<p>该公司的主要上市产品 Syfovre（pegcetacoplan）是一种用于治疗与年龄相关的黄斑变性引起的地理萎缩的玻璃体内补体 C3 抑制剂，目前正在对其他视网膜疾病进行持续研究。</p>
<h2>了解更多</h2>
<ul>
<li>我们更看好的五只股票，胜过 Apellis Pharmaceuticals</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QVBMUw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QVBMUw"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 Apellis Pharmaceuticals 吗？</h2>
<p>在你考虑投资 Apellis Pharmaceuticals 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Apellis Pharmaceuticals 并不在名单上。</p>
<p>虽然 Apellis Pharmaceuticals 目前在分析师中获得了持有评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

APLS

<p>Apellis Pharmaceuticals（纳斯达克代码：APLS）报告的季度每股收益为 0.15 美元，超出预期 0.53 美元。该公司实现收入 2.683 亿美元，超过预期的 2.0358 亿美元。Apellis 的净利润率为 2.23%，股本回报率为 8.20%。尽管财报表现积极，股价仍下跌 0.3%，至 41.01 美元。分析师对该股票的评级不一，普遍目标价为 34.89 美元。该公司专注于开发罕见疾病的治疗方案，其主要产品 Syfovre 已获批准用于地理性萎缩</p>

<p>Apellis Pharmaceuticals (NASDAQ:APLS - Get Free Report) announced its earnings results on Thursday. The company reported $0.15 EPS for the quarter, topping the consensus estimate of ($0.38) by $0.53, FiscalAI reports. Apellis Pharmaceuticals had a net margin of 2.23% and a return on equity of 8.20%. The business had revenue of $268.30 million during the quarter, compared to analysts' expectations of $203.58 million.</p>
<div class="lb-trans"><p>Apellis Pharmaceuticals（纳斯达克代码：APLS - 获取免费报告）于周四公布了其财报。该公司报告本季度每股收益为 0.15 美元，超出市场共识预期的（0.38 美元）0.53 美元，FiscalAI 报道。Apellis Pharmaceuticals 的净利润率为 2.23%，股本回报率为 8.20%。该季度的营业收入为 2.683 亿美元，而分析师的预期为 2.0358 亿美元。</p>
</div><h2>Apellis Pharmaceuticals Stock Down 0.3%</h2>
<div class="lb-trans"><h2>Apellis Pharmaceuticals 股价下跌 0.3%</h2>
</div><ul>
<li>Beam Therapeutics Bolts Higher on Gene Therapy Licensing Payments</li>
</ul>
<div class="lb-trans"><ul>
<li>Beam Therapeutics 因基因治疗许可支付而大幅上涨</li>
</ul>
</div><p>Shares of NASDAQ:APLS traded down $0.11 during midday trading on Thursday, hitting $41.01. The stock had a trading volume of 8,392,532 shares, compared to its average volume of 3,822,692. Apellis Pharmaceuticals has a 12 month low of $16.10 and a 12 month high of $41.14. The company has a quick ratio of 2.70, a current ratio of 3.14 and a debt-to-equity ratio of 0.98. The business's 50-day simple moving average is $30.34 and its 200-day simple moving average is $25.59. The company has a market cap of $5.25 billion, a P/E ratio of 315.49 and a beta of -0.24.</p>
<div class="lb-trans"><p>周四午盘交易中，纳斯达克代码：APLS 的股价下跌 0.11 美元，报 41.01 美元。该股票的交易量为 8,392,532 股，而其平均交易量为 3,822,692 股。Apellis Pharmaceuticals 的 12 个月低点为 16.10 美元，12 个月高点为 41.14 美元。该公司的速动比率为 2.70，流动比率为 3.14，债务股本比率为 0.98。该公司的 50 日简单移动平均线为 30.34 美元，200 日简单移动平均线为 25.59 美元。公司的市值为 52.5 亿美元，市盈率为 315.49，贝塔值为-0.24。</p>
</div><h2>Hedge Funds Weigh In On Apellis Pharmaceuticals</h2>
<div class="lb-trans"><h2>对 Apellis Pharmaceuticals 的对冲基金看法</h2>
</div><p>Several hedge funds and other institutional investors have recently made changes to their positions in the company. Invesco Ltd. grew its stake in shares of Apellis Pharmaceuticals by 23.5% in the fourth quarter. Invesco Ltd. now owns 225,976 shares of the company's stock valued at $5,677,000 after buying an additional 42,960 shares in the last quarter. Mackenzie Financial Corp grew its stake in shares of Apellis Pharmaceuticals by 25.4% in the fourth quarter. Mackenzie Financial Corp now owns 96,211 shares of the company's stock valued at $2,424,000 after buying an additional 19,500 shares in the last quarter. NewEdge Advisors LLC bought a new position in shares of Apellis Pharmaceuticals in the fourth quarter valued at $366,000. Virtus Investment Advisers LLC grew its stake in shares of Apellis Pharmaceuticals by 17.4% in the fourth quarter. Virtus Investment Advisers LLC now owns 27,086 shares of the company's stock valued at $680,000 after buying an additional 4,013 shares in the last quarter. Finally, Twinbeech Capital LP boosted its position in Apellis Pharmaceuticals by 47.3% during the fourth quarter. Twinbeech Capital LP now owns 13,152 shares of the company's stock worth $330,000 after purchasing an additional 4,225 shares during the period. 96.29% of the stock is owned by institutional investors.</p>
<div class="lb-trans"><p>几家对冲基金和其他机构投资者最近对该公司的持仓进行了调整。Invesco Ltd.在第四季度将其在 Apellis Pharmaceuticals 的股份增加了 23.5%。Invesco Ltd.目前拥有 225,976 股该公司的股票，价值 5,677,000 美元，此前在上个季度又购买了 42,960 股。Mackenzie Financial Corp 在第四季度将其在 Apellis Pharmaceuticals 的股份增加了 25.4%。Mackenzie Financial Corp 目前拥有 96,211 股该公司的股票，价值 2,424,000 美元，此前在上个季度又购买了 19,500 股。NewEdge Advisors LLC 在第四季度购买了 Apellis Pharmaceuticals 的新头寸，价值 366,000 美元。Virtus Investment Advisers LLC 在第四季度将其在 Apellis Pharmaceuticals 的股份增加了 17.4%。Virtus Investment Advisers LLC 目前拥有 27,086 股该公司的股票，价值 680,000 美元，此前在上个季度又购买了 4,013 股。最后，Twinbeech Capital LP 在第四季度将其在 Apellis Pharmaceuticals 的持仓增加了 47.3%。Twinbeech Capital LP 目前拥有 13,152 股该公司的股票，价值 330,000 美元，此前在此期间又购买了 4,225 股。96.29% 的股票由机构投资者持有。</p>
</div><h2>Analysts Set New Price Targets</h2>
<div class="lb-trans"><h2>分析师设定新目标价</h2>
</div><ul>
<li>Are Small Caps a Harbinger of Market Declines?</li>
</ul>
<div class="lb-trans"><ul>
<li>小型股是否预示市场下跌？</li>
</ul>
</div><p>Several research analysts recently commented on the stock. Bank of America upgraded shares of Apellis Pharmaceuticals from a &#34;neutral&#34; rating to a &#34;buy&#34; rating and set a $28.00 target price for the company in a report on Wednesday, January 21st. JPMorgan Chase &amp; Co. restated a &#34;neutral&#34; rating and set a $41.00 target price (up from $37.00) on shares of Apellis Pharmaceuticals in a report on Wednesday, April 1st. Barclays increased their target price on shares of Apellis Pharmaceuticals from $24.00 to $41.00 and gave the stock an &#34;equal weight&#34; rating in a report on Wednesday, April 1st. Raymond James Financial cut shares of Apellis Pharmaceuticals from a &#34;moderate buy&#34; rating to a &#34;hold&#34; rating in a report on Wednesday, April 1st. Finally, Wells Fargo &amp; Company cut shares of Apellis Pharmaceuticals from an &#34;overweight&#34; rating to an &#34;equal weight&#34; rating and increased their target price for the stock from $26.00 to $41.00 in a report on Friday, April 17th. Three equities research analysts have rated the stock with a Buy rating, eighteen have given a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat.com, Apellis Pharmaceuticals presently has an average rating of &#34;Hold&#34; and a consensus price target of $34.89.</p>
<div class="lb-trans"><p>几位研究分析师最近对该股票进行了评论。美国银行将 Apellis Pharmaceuticals 的股票评级从 “中性” 上调至 “买入”，并在 1 月 21 日的报告中设定了 28.00 美元的目标价。摩根大通在 4 月 1 日的报告中重申了 “中性” 评级，并将 Apellis Pharmaceuticals 的目标价设定为 41.00 美元（上调自 37.00 美元）。巴克莱在 4 月 1 日的报告中将 Apellis Pharmaceuticals 的目标价从 24.00 美元提高至 41.00 美元，并给予该股票 “等权重” 评级。雷蒙德·詹姆斯金融在 4 月 1 日的报告中将 Apellis Pharmaceuticals 的股票评级从 “适度买入” 下调至 “持有”。最后，富国银行在 4 月 17 日的报告中将 Apellis Pharmaceuticals 的股票评级从 “超配” 下调至 “等权重”，并将该股票的目标价从 26.00 美元提高至 41.00 美元。三位股票研究分析师对该股票给予了买入评级，十八位给予了持有评级，两位给予了卖出评级。根据 MarketBeat.com 的数据，Apellis Pharmaceuticals 目前的平均评级为 “持有”，共识目标价为 34.89 美元。</p>
</div><p><strong>Check Out Our Latest Research Report on APLS</strong></p>
<div class="lb-trans"><p><strong>查看我们最新的 APLS 研究报告</strong></p>
</div><h2>Apellis Pharmaceuticals Company Profile</h2>
<div class="lb-trans"><h2>Apellis Pharmaceuticals 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Apellis Pharmaceuticals, Inc, traded as NASDAQ:APLS, is a clinical-stage biopharmaceutical company focused on the development of novel therapies targeting the complement cascade for the treatment of rare and debilitating diseases. The company's research and development efforts center on modulating complement proteins to address a range of ophthalmologic, hematologic and renal conditions. Apellis leverages its proprietary compstatin technology platform to design targeted inhibitors intended to improve patient outcomes and quality of life.</p>
<div class="lb-trans"><p>Apellis Pharmaceuticals, Inc.，以纳斯达克代码：APLS 交易，是一家临床阶段的生物制药公司，专注于开发针对补体级联反应的新疗法，以治疗罕见且严重的疾病。该公司的研发工作集中在调节补体蛋白，以解决一系列眼科、血液和肾脏疾病。Apellis 利用其专有的 compstatin 技术平台设计针对性抑制剂，旨在改善患者的治疗效果和生活质量。</p>
</div><p>The company's lead marketed product, Syfovre (pegcetacoplan), is an intravitreal complement C3 inhibitor approved for geographic atrophy secondary to age-related macular degeneration, with ongoing investigations in other retinal disorders.</p>
<div class="lb-trans"><p>该公司的主要上市产品 Syfovre（pegcetacoplan）是一种用于治疗与年龄相关的黄斑变性引起的地理萎缩的玻璃体内补体 C3 抑制剂，目前正在对其他视网膜疾病进行持续研究。</p>
</div><h2>Read More</h2>
<div class="lb-trans"><h2>了解更多</h2>
</div><ul>
<li>Five stocks we like better than Apellis Pharmaceuticals</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票，胜过 Apellis Pharmaceuticals</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QVBMUw" alt="" original-src="https://www.marketbeat.com/scripts/EarningsChart.ashx?Prefix=NASDAQ&amp;Symbol=APLS"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Apellis Pharmaceuticals Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Apellis Pharmaceuticals 吗？</h2>
</div><p>Before you consider Apellis Pharmaceuticals, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑投资 Apellis Pharmaceuticals 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Apellis Pharmaceuticals wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Apellis Pharmaceuticals 并不在名单上。</p>
</div><p>While Apellis Pharmaceuticals currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Apellis Pharmaceuticals 目前在分析师中获得了持有评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Apellis Pharmaceuticals (NASDAQ:APLS) Issues Quarterly Earnings Results, Beats Estimates By $0.53 EPS

Market Beat

Apellis Pharma

Beam Therapeutics

景顺投资管理

美国银行

摩根大通

巴克莱银行

瑞杰金融

富国银行

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH INT NON CUM PFD QQ

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '5'

BANK OF AMERICA CORPORATION 7.25% NON-CUM PERP CONV PFD SER L

BANK OF AMERICA CORPORATION 5.875%NON CUM DEP SHS REP1/1000TH SER HH

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '2'

BANK OF AMERICA CORPORATION 5% DEP SHS REPR 1/1000TH NON CUM PFD LL

BANK OF AMERICA CORPORATION DEP SHARES REP 1/1000TH PERP PFD SER 'E'

BANK OF AMERICA CORPORATION INCOME CAPITAL OBLIG NTS DUE 15/12/2066

BANK OF AMERICA CORPORATION 4.375% DP SH RP 1/1000TH IN NON CU PF NN

BANK OF AMERICA CORPORATION DEP SH REP 1/1200TH PRF SER 1 USD25

BANK OF AMERICA CORPORATION 5.375%DEP SHS REP 1/1000TH NON CUM SR KK

BANK OF AMERICA CORPORATION 6%NON CUM DEP SHS EACH REP 1/1000 SER GG

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200 PFD SER 4 USD25

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH NON CUM PFD SER SS

BANK OF AMERICA CORPORATION 4.125%DEP SH REP 1/1000 PFD SER PP USD25

Bank of America Corp

JPMORGAN CHASE & CO. 4.20% DEP SHS REPSTG 1/400TH PFD SER MM

JPMORGAN CHASE & CO. 6%NON CUM DEP SHS REP 1/400TH PFD SER EE

JPMORGAN CHASE & CO. DEP REP 1/400TH (5.75% NON CUM PFD DD)

JPMORGAN CHASE & CO. 4.625% DEP SH RE 1/400TH INT NO CU PF LL

JPMorgan Chase & Co.

JPMORGAN CHASE & CO. 4.55% DEP SHS REPSTG 1/400TH PFD SER JJ

JPMORGAN CHASE & CO. 4.75 DEP SHS REP 1/400 NCUM PFD SR GG

RAYMOND JAMES FINANCIAL INC 6.375%DEP SHS REP 1/40TH FXD FLTG SER B

WELLS FARGO & COMPANY DP SHS REP 1/1000TH INT NCUM PFD CL A DD

WELLS FARGO & COMPANY 7.5% PERP CONV PRF CLS 'A' SERIES 'L'

WELLS FARGO & COMPANY DEP SHS REP 1/1000 INT PER PFD SER Y A

WELLS FARGO & COMPANY DP SHS REP 1/1000TH INT NCUM PFD CL A CC

WELLS FARGO & COMPANY 4.75% DEP SHS 1/1000 NCUM PFD CL A SR Z

WELLS FARGO & COMPANY DEP SHS REP 1/1000TH INT PFD SR AA (CLA)

Apellis Pharmaceuticals（纳斯达克股票代码：APLS）公布季度财报，每股收益比预期高出 0.53 美元